Quick Answer
Doximity, Inc. reported Research And Development Expense of $93.04 million for the year ending 2025.
- Doximity, Inc. showed an increase of +13.5% in Research And Development Expense from 2024 to 2025.
- This data is from Doximity, Inc.'s annual report (Form 10-K), filed with the SEC on May 20, 2025.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $10.04 million | Q3 2020: $9.87 million | Q4 2020: $11.41 million | Q2 2021: $13.24 million | Q3 2021: $15.46 million | Q4 2021: $16.23 million | Q2 2022: $19.02 million | Q3 2022: $19.10 million | Q4 2022: $20.52 million | Q2 2023: $21.93 million | Q3 2023: $19.96 million | Q4 2023: $19.95 million | Q2 2024: $22.57 million | Q3 2024: $23.24 million | Q4 2024: $22.42 million | Q2 2025: $26.80 million | Q3 2025: $30.20 million | Q4 2025: $34.60 million.
- Over the full 6 years of available data (2020 to 2025), Doximity, Inc.'s Research And Development Expense has grown by 186.8%.
- Historical annual values: Fiscal year 2025: $93.04 million | Fiscal year 2024: $81.98 million | Fiscal year 2023: $80.19 million | Fiscal year 2022: $62.35 million | Fiscal year 2021: $43.87 million | Fiscal year 2020: $32.44 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: